There are currently 28 clinical trials in Chesapeake, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Gastroenterology Associates of Tidewater, Investigational Site Number 840025, Cancer Specialists of Tidewater Limited and Virginia Oncology Associaties. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
Recruiting
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
04/08/2024
Locations: Chesapeake Regional Medical Center, Chesapeake, Virginia
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
Register for Updates
A Study of Baricitinib in Participants With Rheumatoid Arthritis
NCT04086745
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Center for Arthritis and Rheumatic Diseases, PC, Chesapeake, Virginia
Conditions: Rheumatoid Arthritis
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Chesapeake Regional Medical Center, Chesapeake, Virginia
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy
NCT04888988
Recruiting
This phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN). CIPN occurs when chemotherapy damages the nerves communicating between the brain, spinal cord, and the rest of the body. The usual approach for treating CIPN is treatment with drugs that help reduce symptoms of other types of neuropathy (for example, from diabetes). However, these drugs do not treat all symptoms of CIPN. Exercise may help to reduce... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Chesapeake Regional Medical Center, Chesapeake, Virginia
Conditions: Chemotherapy-Induced Peripheral Neuropathy
Register for Updates
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Cancer Specialists of Tidewater Limited, Chesapeake, Virginia
Conditions: Stage III Colon Cancer
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Virginia Oncology Associates,744 N. Battlefield Blvd, Chesapeake, Virginia
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Gastroenterology Associates of Tidewater, Chesapeake, Virginia
Conditions: Colitis, Ulcerative
Register for Updates
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
NCT05514535
Recruiting
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Virginia Endo Res, LLC, Chesapeake, Virginia
Conditions: Diabetes Mellitus, Type 2, Obesity
Register for Updates
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
NCT05285553
Recruiting
The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.
Gender:
All
Ages:
Between 8 years and 12 years
Trial Updated:
03/14/2024
Locations: Virginia Pediatric Eye Care, Chesapeake, Virginia
Conditions: Myopia
Register for Updates
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577
Recruiting
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall... Read More
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2024
Locations: Research Site, Chesapeake, Virginia
Conditions: Prostate Cancer
Register for Updates
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy
NCT04829539
Recruiting
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-III cancer who are receiving chemotherapy. Chemotherapy can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia can be described as difficulty falling asleep, waking up many times during the night or waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality of life. This trial may help researchers de... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Chesapeake Regional Medical Center, Chesapeake, Virginia
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
NCT05238142
Recruiting
The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes in a home setting. The combined run-in period and study period will be approximately 135 days long.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/15/2024
Locations: Virginia Endocrinology Research, Chesapeake, Virginia
Conditions: Type 2 Diabetes Treated With Insulin
Register for Updates